Table 3.
Lipidomic variables at baseline and at the end of the study in patients treated with the DHA supplement and in controls.
| Variables | Control Group (n = 15) | DHA Group (n = 19) | Within-Group p Value |
Between-Group p Value |
||||
|---|---|---|---|---|---|---|---|---|
| Baseline | End of Study | Baseline | End of Study | Control Group | DHA Group | Baseline | End of Study | |
| DHA, % total fatty acids | 2.98 (0.19) | 2.97 (0.18) | 3.02 (0.23) | 4.95 (0.13) | 0.945 | <0.0001 | 0.925 | <0.0001 |
| ARA, % total fatty acids | 12.93 (0.16) | 12.58 (0.20) | 12.85 (0.23) | 11.52 (0.25) | 0.009 | <0.0001 | 0.831 | 0.005 |
| n-6 PUFA/n-3 PUFA | 6.61 (0.50) | 6.43 (0.49) | 6.55 (0.51) | 3.79 (0.14) | 0.304 | <0.0001 | 0.878 | <0.0001 |
| Omega-3 index | 3.23 (0.21) | 3.21 (0.19) | 3.30 (0.26) | 5.46 (0.16) | 0.890 | <0.0001 | 0.939 | <0.0001 |
DHA: docosahexaenoic acid; ARA: arachidonic acid; PUFA: polyunsaturated fatty acids. Data expressed as mean and standard error of the mean (SEM).